$85 Billion Payday Can't Rescue Lagging Johnson & Johnson Stock

Johnson & Johnson (JNJ) has sent $85 billion in cash back to its shareholders over the last five years, with about $60 billion paid out as dividends and another $25 billion used for share repurchases. This generosity produced a paradox: despite paying out a fortune, the company's stock lagged the market.

The healthcare giant's sprawling business generated $97.93 billion in revenue over the last twelve months with an operating margin of 27%. However, its stock only produced a total return of +70% during this period, falling short of the S&P 500 index, which returned +83%. This raises questions about whether holding JNJ was worth it and if it still is.

One possible explanation for JNJ's performance imbalance is that management is disciplined in returning capital to shareholders but may be hesitant to reinvest it in new products or acquisitions. The company's Innovative Medicine division is performing well, with some new launches showing strong early momentum. However, the MedTech segment is a growing concern, with a 2% decline in sales of its Abiomed heart pump business.

For JNJ's stock to catch up with the market, the underlying business must prove it can accelerate, particularly in the MedTech division. Management has raised its outlook for full-year operational sales growth and expects the MedTech segment to grow better in the second half than the first. The health of this division will be a key variable for shareholders weighing the value of their dividend checks against the stock's potential.